Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of complement inhibition with eculizumab in adult TA-TMA

Eleni Gavriilaki • 2 Feb 2021
TCT 2021
Eculizumab

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses the results of an analysis aiming to compare strategies and outcomes of patients with transplant-associated thrombotic microangiopathy (TA-TMA) treated with eculizumab. At a median follow-up of 11.1 months, overall survival was found to be significantly higher in patients that received eculizumab, suggesting benefit for complement inhibition in this patient population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Eleni Gavriilaki

0:58
Agents under investigation for the treatment of TA-TMA
Eleni Gavriilaki • 16 Feb 2024
1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:19
The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki • 11 Dec 2023
The content of VJHemOnc is intended for healthcare professionals